Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
BioXcel Therapeutics price target lowered to $140 from $176 at H.C. Wainwright » 06:12
06/28/21
06/28
06:12
06/28/21
06:12
BTAI

BioXcel Therapeutics

$31.09 /

+0.05 (+0.16%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on BioXcel Therapeutics to $140 from $176 and keeps a Buy rating on the shares. Some education appears necessary, but overall market receptivity for BXCL501 should be solid, Selvaraju tells investors in a research note.

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$31.09 /

+0.05 (+0.16%)

BTAI BioXcel Therapeutics
$31.09 /

+0.05 (+0.16%)

06/23/21 Truist
BioXcel Therapeutics price target lowered to $125 from $128 at Truist
06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
BTAI BioXcel Therapeutics
$31.09 /

+0.05 (+0.16%)

  • 23
    Jun
  • 29
    Jul
BTAI BioXcel Therapeutics
$31.09 /

+0.05 (+0.16%)

Conference/Events
BioXcel Therapeutics to hold virtual meeting » 11:25
06/25/21
06/25
11:25
06/25/21
11:25
BTAI

BioXcel Therapeutics

$31.01 /

-0.03 (-0.10%)

Virtual Commercial Day…

Virtual Commercial Day 2021 will be held on June 25 at 12 pm. Webcast Link

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$31.01 /

-0.03 (-0.10%)

BTAI BioXcel Therapeutics
$31.01 /

-0.03 (-0.10%)

06/23/21 Truist
BioXcel Therapeutics price target lowered to $125 from $128 at Truist
06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
BTAI BioXcel Therapeutics
$31.01 /

-0.03 (-0.10%)

  • 23
    Jun
  • 29
    Jul
BTAI BioXcel Therapeutics
$31.01 /

-0.03 (-0.10%)

Conference/Events
BioXcel Therapeutics to hold virtual meeting » 04:55
06/25/21
06/25
04:55
06/25/21
04:55
BTAI

BioXcel Therapeutics

$31.09 /

-0.53 (-1.68%)

Virtual Commercial Day…

Virtual Commercial Day 2021 will be held on June 25 at 12 pm. Webcast Link

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$31.09 /

-0.53 (-1.68%)

BTAI BioXcel Therapeutics
$31.09 /

-0.53 (-1.68%)

06/23/21 Truist
BioXcel Therapeutics price target lowered to $125 from $128 at Truist
06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
BTAI BioXcel Therapeutics
$31.09 /

-0.53 (-1.68%)

  • 23
    Jun
  • 29
    Jul
BTAI BioXcel Therapeutics
$31.09 /

-0.53 (-1.68%)

Syndicate
BioXcel Therapeutics 3.155M share Spot Secondary priced at $31.70 » 08:41
06/23/21
06/23
08:41
06/23/21
08:41
BTAI

BioXcel Therapeutics

$36.88 /

-1.38 (-3.61%)

The deal priced at bottom…

The deal priced at bottom end of $31.70-$33.70 offered range. BofA is acting as sole book running manager for the offering.

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

06/23/21 Truist
BioXcel Therapeutics price target lowered to $125 from $128 at Truist
06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

  • 23
    Jun
  • 29
    Jul
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

Recommendations
BioXcel Therapeutics price target lowered to $125 from $128 at Truist » 07:13
06/23/21
06/23
07:13
06/23/21
07:13
BTAI

BioXcel Therapeutics

$36.88 /

-1.38 (-3.61%)

Truist analyst Robyn…

Truist analyst Robyn Karnauskas lowered the firm's price target on BioXcel Therapeutics to $125 from $128 but keeps a Buy rating on the shares. The analyst cites the company's $100M equity raise but also notes that a financing overhang has been "removed", with the focus now falling on more dementia data in 40mg drug trial and the BXCL501's approval in bipolar disorders and schizophrenia. Checks with key opinion leaders suggest that the drug will be "huge, especially in dementia".

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

  • 23
    Jun
  • 29
    Jul
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

On The Fly
Fly Intel: After-Hours Movers » 18:28
06/22/21
06/22
18:28
06/22/21
18:28
SHAK

Shake Shack

$96.27 /

+1.56 (+1.65%)

, GMTX

Gemini Therapeutics

$9.81 /

-0.445 (-4.34%)

, EYES

Second Sight

$6.33 /

-0.1 (-1.56%)

, SCR

Score Media

$24.14 /

+1.78 (+7.96%)

, BW

Babcock & Wilcox

$7.57 /

-0.2 (-2.57%)

, SELF

Global Self Storage

$5.97 /

-0.14 (-2.29%)

, BTAI

BioXcel Therapeutics

$36.88 /

-1.38 (-3.61%)

, BSY

Bentley Systems

$65.94 /

-0.53 (-0.80%)

, KROS

Keros Therapeutics

$52.64 /

-0.41 (-0.77%)

, WSC

WillScot Mobile Mini

$28.46 /

-0.03 (-0.11%)

Check out this evening's…

ShowHide Related Items >><<
WSC WillScot Mobile Mini
$28.46 /

-0.03 (-0.11%)

SHAK Shake Shack
$96.27 /

+1.56 (+1.65%)

KROS Keros Therapeutics
$52.64 /

-0.41 (-0.77%)

GMTX Gemini Therapeutics
$9.81 /

-0.445 (-4.34%)

EYES Second Sight
$6.33 /

-0.1 (-1.56%)

BW Babcock & Wilcox
$7.57 /

-0.2 (-2.57%)

BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

BSY Bentley Systems
$65.94 /

-0.53 (-0.80%)

SHAK Shake Shack
$96.27 /

+1.56 (+1.65%)

06/07/21 Piper Sandler
Shake Shack shares remain undervalued, says Piper Sandler
05/25/21
Fly Intel: Top five analyst upgrades
05/25/21 Wedbush
Shake Shack upgraded to Outperform from Neutral at Wedbush
05/25/21 Goldman Sachs
Shake Shack upgraded to Buy from Neutral at Goldman Sachs
GMTX Gemini Therapeutics
$9.81 /

-0.445 (-4.34%)

04/08/21 SVB Leerink
SVB Leerink bullish on Gemini Therapeutics, initiates with an Outperform
04/08/21 SVB Leerink
Gemini Therapeutics initiated with an Outperform at SVB Leerink
03/03/21 Jefferies
Gemini Therapeutics initiated with a Buy at Jefferies
03/02/21 Goldman Sachs
Gemini Therapeutics initiated with a Buy at Goldman Sachs
EYES Second Sight
$6.33 /

-0.1 (-1.56%)

SCR Score Media
$24.14 /

+1.78 (+7.96%)

06/22/21 Credit Suisse
Score Media rallies with Credit Suisse positive ahead of sports betting vote
03/23/21 Credit Suisse
Score Media initiated with an Outperform at Credit Suisse
03/22/21 Macquarie
Score Media initiated with an Outperform at Macquarie
BW Babcock & Wilcox
$7.57 /

-0.2 (-2.57%)

03/25/21
Fly Intel: Top five analyst initiations
03/25/21 Lake Street
Babcock & Wilcox initiated with a Buy at Lake Street
03/25/21 DA Davidson
Babcock & Wilcox initiated with a Buy at DA Davidson
02/18/21
Fly Intel: Top five analyst initiations
SELF Global Self Storage
$5.97 /

-0.14 (-2.29%)

04/22/21 Aegis
Global Self Storage initiated with a Buy at Aegis
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
BSY Bentley Systems
$65.94 /

-0.53 (-0.80%)

06/14/21 Mizuho
Bentley Systems price target raised to $74 from $53 at Mizuho
05/24/21 KeyBanc
Bentley Systems price target raised to $60 from $54 at KeyBanc
05/14/21 Goldman Sachs
Bentley Systems assumed with a Neutral at Goldman Sachs
03/10/21
Fly Intel: Top five analyst upgrades
KROS Keros Therapeutics
$52.64 /

-0.41 (-0.77%)

12/08/20 SVB Leerink
Keros Therapeutics price target raised to $80 from $42 at SVB Leerink
12/08/20 H.C. Wainwright
Keros Therapeutics price target raised to $100 from $50 at H.C. Wainwright
12/08/20 Piper Sandler
Keros Therapeutics price target raised to $95 from $75 at Piper Sandler
11/18/20 Piper Sandler
Keros Therapeutics price target raised to $75 from $55 at Piper Sandler
WSC WillScot Mobile Mini
$28.46 /

-0.03 (-0.11%)

05/03/21 Deutsche Bank
WillScot Mobile Mini price target raised to $34 from $31 at Deutsche Bank
03/03/21 Baird
WillScot Mobile Mini upgraded to Outperform from Neutral at Baird
03/02/21 Barclays
WillScot Mobile Mini price target raised to $30 from $23 at Barclays
02/02/21 Deutsche Bank
WillScot Mobile Mini price target raised to $26 from $22 at Deutsche Bank
WSC WillScot Mobile Mini
$28.46 /

-0.03 (-0.11%)

SHAK Shake Shack
$96.27 /

+1.56 (+1.65%)

KROS Keros Therapeutics
$52.64 /

-0.41 (-0.77%)

BW Babcock & Wilcox
$7.57 /

-0.2 (-2.57%)

BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

BSY Bentley Systems
$65.94 /

-0.53 (-0.80%)

  • 23
    Jun
  • 23
    Jun
  • 23
    Jun
  • 23
    Jun
  • 02
    Mar
  • 25
    Feb
  • 10
    Feb
  • 13
    Nov
  • 13
    Nov
  • 23
    Sep
  • 29
    Jul
SCR Score Media
$24.14 /

+1.78 (+7.96%)

EYES Second Sight
$6.33 /

-0.1 (-1.56%)

SHAK Shake Shack
$96.27 /

+1.56 (+1.65%)

SCR Score Media
$24.14 /

+1.78 (+7.96%)

EYES Second Sight
$6.33 /

-0.1 (-1.56%)

BW Babcock & Wilcox
$7.57 /

-0.2 (-2.57%)

BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

SHAK Shake Shack
$96.27 /

+1.56 (+1.65%)

SCR Score Media
$24.14 /

+1.78 (+7.96%)

GMTX Gemini Therapeutics
$9.81 /

-0.445 (-4.34%)

EYES Second Sight
$6.33 /

-0.1 (-1.56%)

BSY Bentley Systems
$65.94 /

-0.53 (-0.80%)

Syndicate
BioXcel Therapeutics announces $100M common stock offering » 16:02
06/22/21
06/22
16:02
06/22/21
16:02
BTAI

BioXcel Therapeutics

$36.88 /

-1.38 (-3.61%)

BioXcel Therapeutics…

BioXcel Therapeutics announced that it has commenced an underwritten public offering of $100M of shares of its common stock. In addition, a related party stockholder, BioXcel LLC, expects to grant the underwriters a 30-day option to purchase up to $15M of additional shares of common stock at the public offering price, less underwriting discounts and commissions. The company intends to use the net proceeds of this offering to fund ongoing clinical trials, commercialization preparation and for general corporate purposes. The company will receive no proceeds from any sale of shares by the selling stockholder. BofA Securities is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

  • 29
    Jul
BTAI BioXcel Therapeutics
$36.88 /

-1.38 (-3.61%)

Conference/Events
BioXcel Therapeutics to hold virtual meeting » 14:44
06/21/21
06/21
14:44
06/21/21
14:44
BTAI

BioXcel Therapeutics

$38.34 /

+0.47 (+1.24%)

Virtual Commercial Day…

Virtual Commercial Day 2021 will be held on June 25 at 12 pm. Webcast Link

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$38.34 /

+0.47 (+1.24%)

BTAI BioXcel Therapeutics
$38.34 /

+0.47 (+1.24%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
BTAI BioXcel Therapeutics
$38.34 /

+0.47 (+1.24%)

  • 29
    Jul
BTAI BioXcel Therapeutics
$38.34 /

+0.47 (+1.24%)

Conference/Events
Goldman Sachs to hold a virtual conference » 04:55
06/10/21
06/10
04:55
06/10/21
04:55
ALNY

Alnylam

$157.41 /

+6.49 (+4.30%)

, FOLD

Amicus

$10.57 /

+0.19 (+1.83%)

, BTAI

BioXcel Therapeutics

$38.91 /

+0.97 (+2.56%)

, TXG

10x Genomics

$185.82 /

-1.29 (-0.69%)

, RPRX

Royalty Pharma

$45.99 /

-0.455 (-0.98%)

, TCDA

Tricida

$4.88 /

+0.16 (+3.39%)

, NEO

NeoGenomics

$42.62 /

+0.72 (+1.72%)

, VIR

Vir Biotechnology

$46.51 /

-0.03 (-0.06%)

, KRON

Kronos Bio

$26.78 /

-0.66 (-2.41%)

, BVS

Bioventus

$17.54 /

+0.42 (+2.45%)

, BHVN

Biohaven Pharmaceutical

$97.57 /

+2.34 (+2.46%)

, RXRX

Recursion Pharmaceuticals

$30.20 /

+0.46 (+1.55%)

, EXEL

Exelixis

$22.78 /

+0.575 (+2.59%)

, DSGN

Design Therapeutics

$27.48 /

-0.02 (-0.07%)

, ARNA

Arena Pharmaceuticals

$62.27 /

+1.3 (+2.13%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 to be held on June 8-10.

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
FOLD Amicus
$10.57 /

+0.19 (+1.83%)

05/27/21 Needham
Amicus initiated with a Hold at Needham
05/27/21 Needham
Amicus initiated with a Hold at Needham
05/20/21 UBS
Amicus initiated with a Buy at UBS
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 William Blair
10x Genomics initiated with an Outperform at William Blair
02/18/21 Cowen
10x Genomics price target raised to $200 from $155 at Cowen
02/18/21 JPMorgan
10x Genomics price target raised to $195 from $160 at JPMorgan
RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

06/03/21 SVB Leerink
MorphoSys upgraded to Outperform at SVB Leerink
11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
TCDA Tricida
$4.88 /

+0.16 (+3.39%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

06/03/21 Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
05/25/21 Truist
NeoGenomics price target lowered to $54 from $65 at Truist
02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Jefferies
Kronos Bio initiated with a Buy at Jefferies
11/03/20 Piper Sandler
Kronos Bio initiated with an Overweight at Piper Sandler
11/03/20 Goldman Sachs
Kronos Bio initiated with a Buy at Goldman Sachs
BVS Bioventus
$17.54 /

+0.42 (+2.45%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

06/01/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $140 from $125 at Cantor Fitzgerald
05/28/21 Mizuho
Biohaven approval should lift 'important overhang,' says Mizuho
05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/12/21 SVB Leerink
Biohaven Pharmaceutical price target lowered to $105 from $115 at SVB Leerink
RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

05/11/21
Fly Intel: Top five analyst initiations
05/11/21 SVB Leerink
SVB Leerink bullish on Recursion Pharmaceuticals, initiates with an Outperform
05/11/21 BofA
BofA starts Recursion Pharmaceuticals at Buy with $31 price target
05/11/21 SVB Leerink
Recursion Pharmaceuticals initiated with an Outperform at SVB Leerink
EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

05/25/21 Stifel
Exelixis' COSMIC-021 cohort 6 results 'incrementally negative,' says Stifel
05/18/21 Goldman Sachs
Exelixis assumed with a Sell at Goldman Sachs
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

05/19/21 Piper Sandler
Reata news should be good for Design Therapeutics, says Piper Sandler
04/20/21 SVB Leerink
SVB Leerink bullish on Design Therapeutics, initiates with an Outperform
04/20/21 SVB Leerink
Design Therapeutics initiated with an Outperform at SVB Leerink
04/20/21 Piper Sandler
Design Therapeutics initiated with an Overweight at Piper Sandler
ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

05/18/21 Goldman Sachs
Arena Pharmaceuticals initiated with a Buy at Goldman Sachs
04/27/21 Citi
Arena Pharmaceuticals initiated with a Buy at Citi
04/26/21 Credit Suisse
Arena Pharmaceuticals assumed with an Outperform at Credit Suisse
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
TXG 10x Genomics
$185.82 /

-1.29 (-0.69%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RPRX Royalty Pharma
$45.99 /

-0.455 (-0.98%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

ALNY Alnylam
$157.41 /

+6.49 (+4.30%)

  • 16
    Apr
  • 26
    Mar
  • 16
    Mar
  • 11
    Feb
  • 07
    Jan
  • 16
    Oct
  • 09
    Oct
  • 11
    Sep
  • 29
    Jul
  • 08
    Jul
  • 16
    Jun
FOLD Amicus
$10.57 /

+0.19 (+1.83%)

VIR Vir Biotechnology
$46.51 /

-0.03 (-0.06%)

TCDA Tricida
$4.88 /

+0.16 (+3.39%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

NEO NeoGenomics
$42.62 /

+0.72 (+1.72%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

EXEL Exelixis
$22.78 /

+0.575 (+2.59%)

DSGN Design Therapeutics
$27.48 /

-0.02 (-0.07%)

BVS Bioventus
$17.54 /

+0.42 (+2.45%)

BTAI BioXcel Therapeutics
$38.91 /

+0.97 (+2.56%)

BHVN Biohaven Pharmaceutical
$97.57 /

+2.34 (+2.46%)

ARNA Arena Pharmaceuticals
$62.27 /

+1.3 (+2.13%)

RXRX Recursion Pharmaceuticals
$30.20 /

+0.46 (+1.55%)

KRON Kronos Bio
$26.78 /

-0.66 (-2.41%)

FOLD Amicus
$10.57 /

+0.19 (+1.83%)

Conference/Events
Goldman Sachs to hold a virtual conference » 11:22
06/09/21
06/09
11:22
06/09/21
11:22
ALNY

Alnylam

$155.41 /

+4.49 (+2.98%)

, FOLD

Amicus

$10.64 /

+0.26 (+2.50%)

, BTAI

BioXcel Therapeutics

$38.75 /

+0.81 (+2.13%)

, TXG

10x Genomics

$188.69 /

+1.58 (+0.84%)

, RPRX

Royalty Pharma

$46.36 /

-0.085 (-0.18%)

, TCDA

Tricida

$4.99 /

+0.27 (+5.72%)

, NEO

NeoGenomics

$42.86 /

+0.96 (+2.29%)

, VIR

Vir Biotechnology

$46.90 /

+0.36 (+0.77%)

, KRON

Kronos Bio

$27.57 /

+0.13 (+0.47%)

, BVS

Bioventus

$17.62 /

+0.5 (+2.92%)

, BHVN

Biohaven Pharmaceutical

$95.97 /

+0.74 (+0.78%)

, RXRX

Recursion Pharmaceuticals

$30.10 /

+0.36 (+1.21%)

, EXEL

Exelixis

$22.47 /

+0.265 (+1.19%)

, DSGN

Design Therapeutics

$27.96 /

+0.46 (+1.67%)

, ARNA

Arena Pharmaceuticals

$61.87 /

+0.9 (+1.48%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference 2021 to be held on June 8-10.

ShowHide Related Items >><<
VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
FOLD Amicus
$10.64 /

+0.26 (+2.50%)

05/27/21 Needham
Amicus initiated with a Hold at Needham
05/27/21 Needham
Amicus initiated with a Hold at Needham
05/20/21 UBS
Amicus initiated with a Buy at UBS
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

06/01/21 H.C. Wainwright
BioXcel Therapeutics price target raised to $176 from $170 at H.C. Wainwright
05/11/21 H.C. Wainwright
BioXcel Therapeutics price target lowered to $170 from $175 at H.C. Wainwright
04/09/21 Berenberg
BioXcel Therapeutics initiated with a Buy at Berenberg
04/01/21 Truist
BioXcel Therapeutics price target lowered to $127 from $150 at Truist
TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

03/15/21
Fly Intel: Top five analyst initiations
03/15/21 William Blair
10x Genomics initiated with an Outperform at William Blair
02/18/21 Cowen
10x Genomics price target raised to $200 from $155 at Cowen
02/18/21 JPMorgan
10x Genomics price target raised to $195 from $160 at JPMorgan
RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

06/03/21 SVB Leerink
MorphoSys upgraded to Outperform at SVB Leerink
11/09/20
Fly Intel: Top five analyst upgrades
11/09/20 UBS
Royalty Pharma upgraded to Buy from Neutral at UBS
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
TCDA Tricida
$4.99 /

+0.27 (+5.72%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

06/03/21 Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
05/25/21 Truist
NeoGenomics price target lowered to $54 from $65 at Truist
02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
02/25/21 Raymond James
NeoGenomics downgraded to Market Perform on valuation at Raymond James
VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

06/03/21 Baird
Vir Biotechnology assumed with a Neutral at Baird
05/27/21 Piper Sandler
Xencorc royalty revenue streams growing, says Piper Sandler
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
03/08/21 H.C. Wainwright
Vir Biotechnology price target raised to $135 from $125 at H.C. Wainwright
KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Jefferies
Kronos Bio initiated with a Buy at Jefferies
11/03/20 Piper Sandler
Kronos Bio initiated with an Overweight at Piper Sandler
11/03/20 Goldman Sachs
Kronos Bio initiated with a Buy at Goldman Sachs
BVS Bioventus
$17.62 /

+0.5 (+2.92%)

03/08/21 Canaccord
Canaccord starts 'medtech execution story' Bioventus with Buy
03/08/21 JPMorgan
Bioventus initiated with an Overweight at JPMorgan
03/08/21 Morgan Stanley
Bioventus initiated with an Overweight at Morgan Stanley
03/08/21 Canaccord
Bioventus initiated with a Buy at Canaccord
BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

06/01/21 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $140 from $125 at Cantor Fitzgerald
05/28/21 Mizuho
Biohaven approval should lift 'important overhang,' says Mizuho
05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/12/21 SVB Leerink
Biohaven Pharmaceutical price target lowered to $105 from $115 at SVB Leerink
RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

05/11/21
Fly Intel: Top five analyst initiations
05/11/21 SVB Leerink
SVB Leerink bullish on Recursion Pharmaceuticals, initiates with an Outperform
05/11/21 BofA
BofA starts Recursion Pharmaceuticals at Buy with $31 price target
05/11/21 SVB Leerink
Recursion Pharmaceuticals initiated with an Outperform at SVB Leerink
EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

05/25/21 Stifel
Exelixis' COSMIC-021 cohort 6 results 'incrementally negative,' says Stifel
05/18/21 Goldman Sachs
Exelixis assumed with a Sell at Goldman Sachs
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Exelixis initiated with an Outperform at Credit Suisse
DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

05/19/21 Piper Sandler
Reata news should be good for Design Therapeutics, says Piper Sandler
04/20/21 SVB Leerink
SVB Leerink bullish on Design Therapeutics, initiates with an Outperform
04/20/21 SVB Leerink
Design Therapeutics initiated with an Outperform at SVB Leerink
04/20/21 Piper Sandler
Design Therapeutics initiated with an Overweight at Piper Sandler
ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

05/18/21 Goldman Sachs
Arena Pharmaceuticals initiated with a Buy at Goldman Sachs
04/27/21 Citi
Arena Pharmaceuticals initiated with a Buy at Citi
04/26/21 Credit Suisse
Arena Pharmaceuticals assumed with an Outperform at Credit Suisse
04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
TXG 10x Genomics
$188.69 /

+1.58 (+0.84%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RPRX Royalty Pharma
$46.36 /

-0.085 (-0.18%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

ALNY Alnylam
$155.41 /

+4.49 (+2.98%)

  • 16
    Apr
  • 26
    Mar
  • 16
    Mar
  • 11
    Feb
  • 07
    Jan
  • 16
    Oct
  • 09
    Oct
  • 11
    Sep
  • 29
    Jul
  • 08
    Jul
  • 16
    Jun
FOLD Amicus
$10.64 /

+0.26 (+2.50%)

VIR Vir Biotechnology
$46.90 /

+0.36 (+0.77%)

TCDA Tricida
$4.99 /

+0.27 (+5.72%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

NEO NeoGenomics
$42.86 /

+0.96 (+2.29%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

EXEL Exelixis
$22.47 /

+0.265 (+1.19%)

DSGN Design Therapeutics
$27.96 /

+0.46 (+1.67%)

BVS Bioventus
$17.62 /

+0.5 (+2.92%)

BTAI BioXcel Therapeutics
$38.75 /

+0.81 (+2.13%)

BHVN Biohaven Pharmaceutical
$95.97 /

+0.74 (+0.78%)

ARNA Arena Pharmaceuticals
$61.87 /

+0.9 (+1.48%)

RXRX Recursion Pharmaceuticals
$30.10 /

+0.36 (+1.21%)

KRON Kronos Bio
$27.57 /

+0.13 (+0.47%)

FOLD Amicus
$10.64 /

+0.26 (+2.50%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.